Heart Patients Are Told to Quit Coffee. A New Trial Disagrees.

Iran talks lapsed, oil climbed and 30-year yields hit a 19-year high. Stocks slipped.

The quick scan: Tuesday was a risk-off session, though not a dramatic one outside technology. President Trump declined to extend the expired US-Iran negotiating window and threatened Oman over the Strait of Hormuz, sending oil higher and reviving inflation worries. Long-dated Treasury yields did most of the damage: the 30-year pushed to a 19-year high, pressuring the richly valued chip and AI names that have led the rally all year. The Dow held up far better than the Nasdaq, and nearly 300 of the S&P 500's members still finished green even as the index slipped for a fourth straight session.

S&P 500: -0.69% to 7,691.76 – off 53.30 points from Monday's 7,745.06 close; almost 300 members rose, but heavyweight tech weakness dragged the index to a fourth straight decline
Dow Jones: -0.22% to 53,343.40 – the most resilient of the majors, surrendering only a fraction of a percent as money rotated toward defensive and value names
NASDAQ: -1.33% to 26,289.71 – the day's clear laggard as semiconductors sold off on rising yields and profit-taking; a widely watched chip gauge fell around 5.5%

What's driving it: Two forces collided. The first is geopolitical: the June memorandum that gave Washington and Tehran a 60-day window to reach a lasting deal expired, and President Trump signalled he would not extend it, keeping the Strait of Hormuz contested and oil bid. West Texas crude traded around $84 and Brent near $91. The second, and bigger, force is the bond market. The 30-year Treasury yield climbed above 5.3%, its highest since 2007, while the 10-year pushed toward 4.7%. Those moves are driven less by the Fed than by persistent inflation risk, heavy government borrowing and a wave of debt tied to the AI build-out. When long yields rise like this, the most expensive corners of the market, chips and AI infrastructure, get repriced first. That is exactly what happened.

Bottom line: For L-Plate Retirees, a day like this is mostly noise. A 0.69% dip in the S&P, with the Dow barely down and most index members higher, is not the real story; the real story is a bond market quietly resetting the price of risk, which matters more for how your fixed-income holdings behave than for any single session. It also rhymes with today's health article: one dramatic-looking data point rarely deserves a dramatic reaction. Note what changed, ask what it means for your own situation, and resist the urge to act on a single day's move.

Heart Patients Are Told to Give Up Coffee. What If That's Wrong?

The scoop: If you have ever been diagnosed with an irregular heartbeat, there is a fair chance the very first instruction you received was to give up your coffee.

It is one of those rules that feels intuitively correct. Caffeine is a stimulant, the heart is misbehaving, so surely the two should be kept well apart. Cardiologists have handed out this advice for decades, and patients have dutifully swapped their morning flat white for something warm, beige and faintly disappointing. A new randomized trial suggests that particular sacrifice may have been unnecessary all along.

The trial is called DECAF, and it set out to test a question most people assumed had been settled long ago: does coffee actually make an irregular heartbeat worse?

What the trial actually did.

DECAF enrolled 200 patients living with persistent atrial fibrillation or atrial flutter, the medical terms for a heart that has fallen out of its normal rhythm. Every participant had just undergone electrical cardioversion, a procedure that resets the heartbeat with a carefully controlled shock. The open question was whether they could hold onto that restored rhythm, and whether coffee would help them or betray them.

Half the group was asked to drink at least one cup of caffeinated coffee every single day. The other half was asked to give up coffee and caffeine entirely. The researchers then followed both groups for six months, watching to see whose irregular heartbeat returned. By the end, the coffee drinkers were averaging about seven cups a week; the abstainers, as instructed, had none. It was, in other words, a fair and deliberate test: one group living the way patients are usually told to live, the other living the way they are usually warned against.

The result that caught the researchers off guard.

The coffee drinkers did better. Over the six months, the group drinking a daily cup had a 39% lower risk of their atrial fibrillation coming back than the group that gave it up completely. For readers who like the technical detail, that is a hazard ratio of 0.61, with a confidence interval of 0.42 to 0.89 and a P value of 0.01, which in plain terms means the result is unlikely to be a fluke of chance. Just as importantly, there was no difference in adverse events between the two groups. Nobody's heart fared worse for the coffee.

Read that twice, because it cuts against nearly everything heart-rhythm patients have been told. The group that kept drinking coffee had fewer recurrences of the very condition coffee was supposed to inflame.

Why the old advice made sense.

It helps to understand where the "avoid coffee" rule came from, because it was not plucked out of thin air. Caffeine is a stimulant that can raise heart rate and blood pressure in the short term, and for years it was quietly lumped in with the things a fluttering heart did not need. The logic was tidy and cautious, and cautious advice is easy to give and awkward to argue against. When a worried patient asked "should I cut out coffee?", the safe answer was always yes. What was missing was evidence that the caution actually helped anyone. Several large observational studies had already hinted that coffee drinkers were at no greater risk of rhythm problems, and a few pointed the other way. DECAF matters because it did not merely observe people and their habits. It randomly assigned them to drink or abstain, which is a far more powerful way to separate cause from coincidence.

What the study does not say.

This is the part that matters most, and it is where a little discipline goes a long way. The researchers behind DECAF are not claiming that coffee protects your heart, and neither am I. A single trial of 200 people followed for six months is a promising signal, not a final verdict. It shows that a daily coffee did no harm and was linked to fewer recurrences in one specific group: people with a diagnosed rhythm disorder who had just had their hearts reset. It does not show that coffee is medicine, and it certainly does not mean everyone should start drinking more of it. The authors themselves have called for larger trials, which is precisely what careful scientists say when a small study lands a surprising result. Curiosity is the right response here, not conversion.

What this means for the rest of us.

Most of us do not live with atrial fibrillation, so this particular finding may never touch our morning routine. But the deeper lesson travels a good deal further than the coffee cup. A great deal of health advice hardens into rule long before the evidence has caught up, and then it gets repeated so often that questioning it starts to feel reckless. "Avoid coffee" was reasonable caution dressed in the clothing of settled fact. It took someone actually running the experiment to discover the caution may have been misplaced.

That is not licence to ignore your doctor and pour a celebratory third cup. If you live with a heart-rhythm condition, the sensible move is not to rewrite your habits on the strength of a newsletter. It is to bring this study to your next appointment and ask what it means for you specifically. Your cardiologist knows your history; a trial of 200 strangers does not.

What the rest of us can take away is gentler permission to hold our health rules a little more loosely. The advice that felt ironclad in 1995 is not always the advice that survives 2026. Staying curious, reading the new evidence, asking the slightly awkward question and being willing to update your mind, is itself a quiet form of looking after yourself. Especially in the years when the advice matters most.

Actionable takeaways for L-Plate Retirees:

• Old health advice is not automatically current health advice. The instruction to avoid coffee with an irregular heartbeat was handed down for decades on caution alone. DECAF is the first randomized trial to test it head on, and the caution did not hold up. Rules can quietly outlive the evidence that created them, and this is a clean example of exactly that.

• A single small trial is a signal, not a verdict. DECAF followed 200 people for six months. That is enough to raise a serious eyebrow, not enough to overturn medical practice on its own. Treat one surprising study as an invitation to ask better questions, never as a reason to make big changes on the spot.

• Take new findings to your doctor, not straight to your kitchen. If you have atrial fibrillation or any heart-rhythm condition, this is the takeaway that counts. Do not adjust your caffeine based on a headline or a newsletter. Bring the study to your next appointment and let someone who knows your full history weigh in on what it means for you.

• "Linked to fewer recurrences" is not the same as "prevents them." The coffee group had fewer relapses, but the researchers stopped short of calling coffee protective, and so should we. Randomized trials get us closer to cause than most studies can, yet one modest trial still earns cautious interest, not certainty.

• Curiosity is a health habit in its own right. The people who age well tend to be the ones who keep reading, keep asking and keep updating what they believe as the evidence shifts. You do not need a medical degree to do this. You need the willingness to notice when a long-held rule deserves a fresh look.

Your Turn: 
What is one piece of health advice you have followed for years without ever checking whether the evidence behind it still holds? 
When a new study contradicts something you have long believed, is your first instinct curiosity or suspicion, and which one has served you better? 
If a fresh headline and your doctor's long-standing advice disagree, how do you decide who to trust?

👉 Hit reply and share your thoughts – your answers could inspire fellow readers in future issues.

If this issue nudged you to hold an old health rule a little more loosely and to take the new evidence to your doctor rather than your kitchen, consider shouting L-Plate Retiree a coffee on Ko-fi. Your support keeps these evidence-checked health reads landing in your inbox six days a week.